Literature DB >> 24489015

Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Neil Basu1, Andrew McClean, Lorraine Harper, Esther N Amft, Neeraj Dhaun, Raashid A Luqmani, Mark A Little, David R W Jayne, Oliver Flossmann, John McLaren, Vinod Kumar, Lars P Erwig, David M Reid, Gary J Macfarlane, Gareth T Jones.   

Abstract

OBJECTIVES: ANCA-associated vasculitis (AAV) commonly affects those of working age. Since survival rates have been transformed by immunotherapeutics, the measurement of other outcomes has become increasingly relevant. Work disability is an important outcome for both patient and society that has yet to be fully evaluated in AAV. We aimed to assess employment status in AAV patients and identify putative predictors of their work disability.
METHODS: A cross-sectional study was undertaken. AAV cases were recruited according to consecutive clinic attendance. Subjects completed a questionnaire that determined employment status and other psychosocial measures. Clinical factors were concurrently recorded by the attending physician. From the data of those subjects of working age, a multivariable model was developed using forward stepwise logistic regression to identify the independent associations of work disability, defined by those subjects reporting unemployment secondary to ill-health. Results are expressed as odds ratios (ORs) and 95% CIs.
RESULTS: Of the 410 participants (84.4% response rate), 149 (36.7%) were employed, 197 (48.6%) retired and 54 (13.3%) unemployed secondary to ill health. Of those of working age, 26.0% were considered work disabled. Fatigue (OR 7.1, 95% CI 1.5, 33.1), depression (OR 4.4, 95% CI 1.8, 10.8), severe disease damage [Vasculitis Damage Index (VDI) > 4 (OR 3.9, 95% CI 1.01, 14.7)] and being overweight (OR 3.4, 95% CI 1.3, 8.9) were independently associated with their unemployment.
CONCLUSION: A quarter of working-age AAV subjects reported unemployment as a result of ill health and are characterized by high levels of fatigue, depression, disease damage and being overweight. These potentially modifiable factors may inform future multidisciplinary interventions aimed at alleviating work disability.

Entities:  

Keywords:  ANCA-associated vasculitis; fatigue; work disability

Mesh:

Year:  2014        PMID: 24489015     DOI: 10.1093/rheumatology/ket483

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

Review 1.  Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases.

Authors:  Natalie McCormick; Carlo A Marra; J Antonio Aviña-Zubieta
Journal:  Curr Rheumatol Rep       Date:  2017-10-30       Impact factor: 4.592

2.  Impact of vasculitis on employment and income.

Authors:  Lillian Barra; Renée L Borchin; Cristina Burroughs; George C Casey; Carol A McAlear; Antoine G Sreih; Kalen Young; Peter A Merkel; Christian Pagnoux
Journal:  Clin Exp Rheumatol       Date:  2018-01-10       Impact factor: 4.473

Review 3.  Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.

Authors:  Kristen Davies; Emma Dures; Wan-Fai Ng
Journal:  Nat Rev Rheumatol       Date:  2021-10-01       Impact factor: 20.543

4.  Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis.

Authors:  Andrea Hinojosa-Azaola; Ariadna Jiménez-González; Natasha Alcocer-Castillejos
Journal:  Rheumatol Int       Date:  2017-12-15       Impact factor: 2.631

5.  Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.

Authors:  Joanna C Robson; Jill Dawson; Helen Doll; Peter F Cronholm; Nataliya Milman; Katherine Kellom; Susan Ashdown; Ebony Easley; Don Gebhart; Georgia Lanier; John Mills; Jacqueline Peck; Raashid Ahmed Luqmani; Judy Shea; Gunnar Tomasson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2018-04-25       Impact factor: 19.103

6.  The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis.

Authors:  Bradley Pittam; Sonal Gupta; Ashar E Ahmed; David M Hughes; Sizheng Steven Zhao
Journal:  Rheumatol Int       Date:  2020-06-04       Impact factor: 2.631

7.  Addressing the transition to a chronic condition: exploring independent adoption of self-management by patients with ANCA-associated vasculitis.

Authors:  Ian Litchfield; Sheila Greenfield; Lorraine Harper
Journal:  Rheumatol Adv Pract       Date:  2021-11-04

8.  Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure.

Authors:  Joanna C Robson; Jill Dawson; Peter F Cronholm; Nataliya Milman; Katherine S Kellom; Susan Ashdown; Ebony Easley; John T Farrar; Don Gebhart; Georgia Lanier; Carol A McAlear; Jacqueline Peck; Raashid A Luqmani; Judy A Shea; Gunnar Tomasson; Peter A Merkel
Journal:  Patient Relat Outcome Meas       Date:  2018-01-04

9.  Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Christina V Golemati; Clio P Mavragani; Sophia Lionaki; Dimitrios Karaiskos; Haralampos M Moutsopoulos
Journal:  Front Psychiatry       Date:  2017-12-15       Impact factor: 4.157

10.  Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study.

Authors:  Lorraine Harper; Matthew David Morgan; Dimitrios Chanouzas; Hollie K Caulfield; Linda Coughlan; Caroline Dean; Kate Fletcher; Fiona Cramp; Sheila Greenfield; Catherine A Hewitt; Natalie J Ives; Sue Jowett; Amanda Daley
Journal:  BMJ Open       Date:  2018-10-30       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.